Monkeypox Vaccination

New Yorkers who may have been exposed to monkeypox in areas with high levels of transmission may be eligible for the JYNNEOS vaccine. Vaccine supply from the federal government is currently limited, and eligibility is expected to expand as supply increases.

What is the JYNNEOS vaccine?

JYNNEOS is a vaccine licensed by the U.S. Food and Drug Administration (FDA) as a two-dose series for the prevention of monkeypox among adults ages 18 years and older. If given before exposure or within 4 days of exposure, this vaccine may reduce the likelihood of infection, and within 14 days, it may reduce severity of symptoms.

The two vaccine doses are given 28 days apart, and New Yorkers are considered fully vaccinated two weeks after their second dose. People who get vaccinated should continue to take steps to protect themselves from infection by avoiding close, skin-to-skin contact, including intimate contact, with someone who has monkeypox.

Availability of the JYNNEOS vaccine:

JYNNEOS is currently only available through the federal government's National Strategic Stockpile. At this time, it is being made available by the federal government for the primary purpose of post-exposure prophylaxis (PEP) among individuals with a possible recent exposure to monkeypox.

Am I eligible for the JYNNEOS vaccine?

In the United States and New York, there is currently a limited supply of JYNNEOS vaccine, though more is expected in the weeks and months ahead. New York State is committed to an equitable distribution of vaccine, and eligibility is currently focused on individuals with known or likely exposure in areas with the highest number of cases.

Based on CDC guidance, and in working with local public health authorities including the New York City Department of Health and Mental Hygiene (NYCDOHMH), Statewide eligibility currently includes the following New Yorkers:

  • Individuals with recent exposure to a suspected or confirmed monkeypox case within the past 14 days.
  • Those at high risk of a recent exposure to monkeypox, including gay men and members of the bisexual, transgender, and gender non-conforming community and other communities of men who have sex with men and who have engaged in intimate or skin-to-skin contact with others in the past 14 days areas where monkeypox is spreading.
  • Individuals who have had skin-to-skin contact with someone in a social network experiencing monkeypox activity, including men who have sex with men who meet partners through an online website, digital application ("app"), or social event, such as a bar or party.

Where is the JYNNEOS vaccine available?

At this time, the limited supply of vaccine doses for New York State have been allocated to Suffolk County, Westchester County, Nassau County, Saratoga County, Rockland County, and Sullivan County, counties with confirmed cases, with a small number of doses used by NYSDOH to distribute to close contacts of known cases, healthcare workers who are exposed on the job, and as they are needed elsewhere throughout the State.

NYSDOH is aware of the high demand for vaccine compared to the currently supply, and more doses will be needed from the federal government to meet the prevention needs of residents. Additional allocations are anticipated in the coming weeks and months.

Where can I get the JYNNEOS vaccine?

People identified by a local health department as exposed to a suspected or confirmed monkeypox case in the past 14 days should work directly with their health department and healthcare provider to discuss obtaining the JYNNEOS vaccine.

Local county health departments that have received a supply will administer the vaccine directly and are establishing their own appointment processes. Please refer to county webpages for more information.

Where can I learn more about the JYNNEOS vaccine?

New Yorkers can learn more about the JYNNEOS vaccine, including the risks and benefits, here. To better understand the protective benefits of the JYNNEOS vaccine in the current outbreak U.S., public health agencies are collecting data to study any side effects, the extent of protection, and whether the way a person was infected makes any difference in how well the vaccine protects them.